Showing results (141-150 of 3,469) with videos related to
Sort By:
Pageof 347
Clinical Pharmacokinetics|May 31, 2002
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitorsDavid Williams, John FeelyClinical Pharmacokinetics|June 10, 2003
Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challengesCollen M Masimirembwa, Ulf Bredberg, Tommy B AnderssonClinical Pharmacokinetics|June 10, 2003
Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitorNeal M Davies, Xiao W Teng, Neil M SkjodtClinical Pharmacokinetics|July 8, 2003
Pharmacological effects of formulation vehicles : implications for cancer chemotherapyAlbert J ten Tije, Jaap Verweij, Walter J Loos, et al.Clinical Pharmacokinetics|November 8, 2019
Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Blood Components and Binding ProteinsKhaled Abduljalil, Masoud Jamei, Trevor N JohnsonClinical Pharmacokinetics|February 8, 2019
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case StudiesNeil A Miller, Micaela B Reddy, Aki T Heikkinen, et al.Clinical Pharmacokinetics|December 20, 2019
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug InteractionsXia Li, Sebastian Frechen, Daniel Moj, et al.Clinical Pharmacokinetics|November 28, 2019
Omadacycline: A Review of the Clinical Pharmacokinetics and PharmacodynamicsKeith A Rodvold, Rodrigo M Burgos, Xing Tan, et al.Clinical Pharmacokinetics|February 16, 2020
Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I TrialManuela Vay, Marleen Julia Meyer, Antje Blank, et al.Clinical Pharmacokinetics|October 1, 1988
The influence of renal function on clinical pharmacokinetics of moxonidineW Kirch, H J Hutt, V PlänitzPageof 347